Lv1
70 积分 2022-10-21 加入
Recent process in the development of TIM-3 antibodies and small-molecule inhibitors for cancer immunotherapy
2个月前
已完结
New immune cell engagers for cancer immunotherapy
2个月前
已完结
Unlocking the potential of T cell engagers in solid tumors
2个月前
已完结
The present and future of bispecific antibodies for cancer therapy
3个月前
已完结
A roadmap to competitive preclinical packages
4个月前
已完结
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer
4个月前
已完结
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
4个月前
已完结
MYC in cancer: from undruggable target to clinical trials
5个月前
已完结
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies
5个月前
已完结
Consensus on the lung cancer management after third-generation EGFR-TKI resistance
6个月前
已完结
皖公网安备34019202002308
